Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24720818 | 0.89 | CRBN (0.42) | CRBNCYP11B1CYP11B2TSHR | |
| SCHEMBL16189944 | 0.85 | — | — | |
| SCHEMBL13636691 | 0.82 | GABRD (0.37) | CRBNCYP11B1CYP11B2TSHRALDH1A1 | |
| SCHEMBL13339631 | 0.79 | TSHR (0.33) | TSHRALDH1A1HPGDHSD17B10CYP2D6 | |
| SCHEMBL22914739 | 0.79 | CRBN (0.43) | CRBNCYP11B1CYP11B2 | |
| SCHEMBL12243268 | 0.79 | CYP11B1 (0.44) | CRBNCYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL1753879 | 0.78 | CYP11B1 (0.50) | CRBNCYP11B1CYP11B2TSHRLRRK2 | |
| Hydrochloric Acid SCHEMBL29407438 | 0.78 | CRBN (0.42) | CRBNCYP11B1CYP11B2 | |
| SCHEMBL10111396 | 0.77 | TSHR (0.39) | TSHRALDH1A1HPGDHSD17B10CYP2D6 | |
| SCHEMBL20941865 | 0.77 | OPRM1 (0.34) | CYP11B1CYP11B2TSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101028-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-03-27 | — | — | US | disclosed |
| EP-4499639-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| CN-118900838-A | Heterocyclic compounds, compositions thereof and methods of treatment thereof | 百济神州有限公司 | 2024-11-05 | — | — | CN | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023179703-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023116865-A1 | PYRAZOLE-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 优领医药科技（上海）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| EP-1518855-B1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| WO-2008068265-A1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | CRBN 3893/4885CYP11B1 25/4885CYP11B2 62/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | CRBN 2602/4885CYP11B1 609/4885CYP11B2 668/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | CRBN 3683/4885CYP11B1 3412/4885CYP11B2 2497/4885 |
| US-20250101028-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | KRAS, NRAS, HRAS | CRBN 396/4885CYP11B1 343/4885CYP11B2 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.